IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

"Harnessing CDK4 Inhibitors For Cancer Therapy: Mechanisms, Clinical Advances, And Future Directions"

Saurav Vasant Pathak[1]*, Yogini Vilas Patil [2], Rajshree Wagh[3]

[1,2,3] Department of Pharmaceutical Chemistry, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India.

Abstract: Cancer is a complex disease characterized by uncontrolled cell proliferation, often driven by genetic and epigenetic alterations that disrupt normal cell cycle regulation. Among the key players in cell cycle progression, cyclin-dependent kinase 4 (CDK4) plays a pivotal role in facilitating the transition from the G1 phase to the S phase by phosphorylating the retinoblastoma (RB) protein. Overactivity of CDK4, whether due to genetic mutations, amplification, or dysregulated signaling pathways, has been implicated in the pathogenesis of various malignancies, including breast cancer, melanoma, glioblastoma, and sarcomas. CDK4 inhibitors, such as Palbociclib, Abemaciclib, and Ribociclib, have emerged as promising therapeutic agents that exert dual anti-cancer effects: they induce cell cycle arrest and promote apoptotic cell death. These inhibitors prevent RB phosphorylation, thereby maintaining its tumor suppressor activity and restricting E2F-dependent transcription. In addition to their role in cell cycle inhibition, growing evidence suggests that CDK4 inhibitors enhance apoptotic signaling by modulating key pathways involving p53 activation, Bcl-2 family proteins, and caspase cascades. This review comprehensively explores the molecular mechanisms through which CDK4 inhibitors regulate apoptotic pathways, their therapeutic potential in cancer treatment, ongoing clinical applications, and the future prospects of CDK4-targeted therapies in overcoming resistance and improving patient outcomes.

Keywords: CDK 4, Cancer, Apoptosis, Necroptosis, Cell Death

1. INTRODUCTION

Cancer arises from disrupting normal cellular processes, particularly those governing the cell cycle. Cyclin-dependent kinases (CDKs) play a pivotal role in cell cycle progression, and their dysregulation is a hallmark of tumorigenesis. Among these, CDK4, associated with cyclin D, is a critical regulator of the G1-S transition, primarily through phosphorylation of the retinoblastoma (RB) protein. This phosphorylation event leads to the release of E2F transcription factors, which promote the transcription of genes required for DNA replication and S-phase entry (1). Aberrant activation of CDK4, often due to genetic mutations, overexpression of cyclin D, or loss of RB function, results in unchecked cellular proliferation and contributes significantly to oncogenesis. Elevated CDK4 activity has been observed in various malignancies, including breast cancer, melanoma, glioblastoma, and sarcomas, and is often associated with poor prognosis and resistance to conventional therapies (2).

Targeting CDK4 with specific inhibitors has shown significant promise in halting tumor growth and inducing apoptosis in cancer cells. CDK4 inhibition leads to sustained RB hypophosphorylation, effectively blocking cell cycle progression and triggering apoptotic pathways via multiple molecular mechanisms, including modulation of p53 activity, disruption of Bcl-2 family protein interactions, and activation of caspase cascades (3). This review provides an in-depth exploration of the role of CDK4 in cancer progression, the

mechanistic pathways through which its inhibition induces apoptosis, and the broader therapeutic implications of CDK4-targeted drugs in clinical oncology.

2. CDK4 AND ITS ROLE IN CANCER

CDK4 is a serine/threonine kinase that is critical in regulating the cell cycle, specifically the G1-S transition. It functions in complex with cyclin D to phosphorylate the retinoblastoma (RB) protein, which dissociates E2F transcription factors. This dissociation allows for the transcription of genes necessary for DNA replication and cell cycle progression (4). In many cancers, CDK4 activity is upregulated due to several oncogenic mechanisms. These include gene amplification, leading to increased CDK4 protein levels, overexpression of cyclin D due to oncogenic signaling pathways (such as aberrant activation of the RAS-RAF-MEK-ERK pathway), and loss of functional RB, which normally acts as a tumor suppressor by inhibiting E2F activity. The deregulation of these pathways results in uncontrolled cell proliferation, making CDK4 a compelling target for therapeutic intervention in various malignancies, including breast cancer, melanoma, glioblastoma, and sarcomas (5).

2.1 Mechanism of CDK4 in Cell Cycle Regulation

CDK4 plays a crucial role in regulating the G1 phase of the cell cycle by forming a complex with cyclin D to phosphorylate the retinoblastoma (RB) protein. This phosphorylation event releases E2F transcription factors, which promote the transcription of genes essential for S-phase entry, such as those involved in DNA synthesis and replication. Under normal physiological conditions, this checkpoint ensures that cells only proceed when favorable conditions exist, such as adequate nutrient availability and the absence of DNA damage (6). However, in cancer, mutations or alterations in signaling pathways often result in constitutive CDK4 activation. These changes can arise due to CDK4 gene amplification, cyclin D overexpression, or RB loss-of-function mutations, leading to unchecked phosphorylation of RB. Consequently, E2F transcription factors remain active, driving continuous cell cycle progression even without external mitogenic signals. This dysregulation disrupts normal growth control mechanisms and contributes to uncontrolled cell division, a hallmark of cancer progression (7).

2.2 CDK4 Overexpression in Cancer

Several malignancies exhibit CDK4 overexpression, including breast cancer, melanoma, glioblastoma, and sarcomas. This overexpression is frequently associated with genetic alterations such as CDK4 gene amplification, chromosomal rearrangements, and enhanced cyclin D expression, all contributing to increased kinase activity. The elevated CDK4 levels drive uncontrolled cell proliferation, disrupt normal cell cycle checkpoints, and promote tumor progression. Moreover, this overexpression correlates with poor prognosis and resistance to standard chemotherapy, emphasizing the necessity of CDK4-targeted interventions to improve treatment outcomes in these aggressive cancers (8).

3. CDK4 INHIBITORS: MECHANISM OF ACTION

CDK4 inhibitors are small-molecule drugs that specifically target CDK4/6 kinase activity, preventing the phosphorylation of the retinoblastoma (RB) protein and thereby halting cell cycle progression at the G1 phase. By maintaining RB in its hypophosphorylated state, these inhibitors effectively suppress E2F-dependent transcription, leading to a sustained cell cycle arrest. In addition to blocking proliferation, recent studies have demonstrated that CDK4 inhibitors also promote apoptosis, senescence, and immune modulation, further enhancing their therapeutic potential in cancer treatment (9).

3.1 Types of CDK4 Inhibitors

CDK4 inhibitors are a class of targeted therapies that specifically inhibit the activity of cyclin-dependent kinase 4 (CDK4) and its closely related partner, CDK6, to halt cancer cell proliferation by preventing cell cycle progression at the G1 phase. Among the most well-established CDK4/6 inhibitors are Palbociclib, Abemaciclib, and Ribociclib, all of which have been approved for treating hormone receptor-positive (HR+) and HER2-negative advanced breast cancer. However, ongoing research is exploring their broader therapeutic applications across various malignancies (10).

Palbociclib (PD-0332991) is a highly selective CDK4/6 inhibitor that functions by blocking the phosphorylation of the retinoblastoma (RB) protein, a key regulator of the cell cycle. By preventing RB phosphorylation, Palbociclib effectively induces G1 phase arrest, thereby slowing or stopping the proliferation of cancer cells. This inhibitor has been FDA-approved for HR+/HER2- advanced or metastatic breast cancer in combination with endocrine therapy, demonstrating significant improvements in progression-free survival and overall patient outcomes in clinical trials. Additionally, ongoing research is investigating its role in other malignancies, including lung cancer and glioblastoma, where CDK4/6 dysregulation plays a role in tumor progression. Some studies suggest that Palbociclib could be beneficial either as a monotherapy or in combination with other targeted therapies, particularly in cancers exhibiting RB pathway dependency (11).

Abemaciclib is another highly selective CDK4/6 inhibitor, distinguished by its ability to exert continuous target inhibition, resulting in sustained cell cycle suppression. Unlike other CDK4 inhibitors, Abemaciclib has a distinct pharmacokinetic profile that allows for its use as a monotherapy, making it particularly effective in some HR+/HER2- breast cancers. Beyond breast cancer, preclinical and clinical studies have demonstrated its efficacy in treating glioblastoma and lung cancer, highlighting its potential in malignancies beyond hormone-dependent cancers. In addition to inducing cell cycle arrest, Abemaciclib has been shown to enhance apoptosis and modulate immune system responses, suggesting its role in combination therapies with immunotherapy and other targeted agents to maximize anti-tumor efficacy (12).

Ribociclib is a potent and selective CDK4/6 inhibitor that, like Palbociclib, inhibits CDK4/6-mediated RB phosphorylation, leading to sustained G1 phase arrest and suppression of tumor growth. It is FDA-approved for use in combination with endocrine therapy in HR+/HER2- advanced breast cancer. It has demonstrated notable improvements in progression-free survival when used alongside aromatase inhibitors or fulvestrant. Beyond breast cancer, ongoing research is evaluating Ribociclib's potential in lung and pancreatic cancers, with particular interest in its role in combination therapies that target complementary pathways involved in tumor growth and resistance mechanisms (13).

As research advances, these CDK4/6 inhibitors are increasingly being explored beyond breast cancer, particularly in cancers where CDK4/6 activity is implicated in tumorigenesis. Their ability to synergize with chemotherapy, immunotherapy, and other targeted agents makes them promising candidates for expanded therapeutic applications, with the potential to improve survival outcomes across multiple cancer types (14). All the therapies for CDK 4 inhibitors in Apoptotic cancer are summarized in Table 1.

Table 1: Approved and Investigational CDK4 Inhibitors in Cancer Therapy

CDK4 Inhibitor	Mechanism of Action	Approved Uses	Clinical Trial Status	Apoptotic Pathway Affected	Key Molecular Players	Reference
Palbociclib	Selective CDK4/6 inhibitor, causes G1 arrest	HR+/HER2− Breast Cancer	FDA Approved	p53-dependent apoptosis	p53, p21, Caspases	(15)
Ribociclib	Inhibits CDK4/6, prevents Rb phosphorylation	HR+/HER2− Breast Cancer	FDA Approved	Bcl-2 family regulation	Bcl-2, Bax, Bad	(16)
Abemaciclib	Inhibits CDK4/6, promotes apoptosis	HR+/HER2− Breast Cancer, NSCLC	FDA Approved	Mitochondrial apoptosis	Cytochrome C, APAF1	(17)
Trilaciclib	Myeloprotective CDK4/6 inhibitor	Small Cell Lung Cancer (SCLC)	FDA Approved	Intrinsic & Extrinsic apoptosis	Caspase-8, FasL, TRAIL	(18)
Dalpiciclib	Selective CDK4/6 inhibitor	HR+ Breast Cancer	Phase III	p53-independent apoptosis	MDM2, E2F1	(19)
Voruciclib	CDK4/6 and CDK9 inhibitor	Hematologic Malignancies	Phase I	CDK9-mediated apoptosis	Bcl-2, Mcl-1, Caspase-3	(20)
Fascaplysin	Natural product, selective CDK4 inhibitor	Experimental	Preclinical	Selective CDK4-mediated apoptosis	Cyclin D1, p21, p27	(21)
FLX925	Dual CDK4/FLT3 inhibitor	Acute Myeloid Leukemia (AML)	Phase I	Dual CDK4/FLT3 inhibition	FLT3, Caspases, Bcl-xL	(22)
PF-06873600	Selective CDK2/4/6 inhibitor	Solid Tumors	Phase I/II	CDK4-dependent apoptosis	pRb, Cyclin D	(23)

3.2 Molecular Mechanism of CDK4 Inhibition

CDK4 inhibitors function by preventing the phosphorylation of the retinoblastoma (RB) protein, thereby preserving its tumor suppressor role and maintaining repression of E2F-dependent transcription. This results in sustained G1-phase arrest, blocking DNA replication and cell cycle progression. Additionally, recent studies indicate that CDK4 inhibitors contribute to apoptosis induction through multiple mechanisms, including modulation of the p53 pathway, regulation of Bcl-2 family proteins, and activation of caspase cascades. These effects collectively enhance the therapeutic potential of CDK4 inhibitors, not only in controlling tumor proliferation but also in promoting programmed cell death in various cancer types (24).

4. CDK4 INHIBITION AND APOPTOSIS

Apoptosis, or programmed cell death, is an essential physiological process that eliminates damaged, mutated, or excess cells, thereby maintaining tissue homeostasis. In cancer, evasion of apoptosis is a hallmark that enables tumor cells to survive and proliferate unchecked. CDK4 inhibitors have been shown to induce cell cycle arrest and trigger apoptotic pathways through multiple mechanisms. These include stabilizing pro-apoptotic proteins, modulation of survival signaling pathways, and direct activation of caspase-dependent cell death. Research has demonstrated that CDK4 inhibition enhances the apoptotic response, particularly in cancers with functional retinoblastoma (RB) protein, reinforcing their role as potential therapeutic agents in targeted cancer therapy (25).

4.1 p53-Dependent Pathway

CDK4 inhibition stabilizes p53 by preventing its degradation through the MDM2 ubiquitin-proteasome pathway. This leads to the upregulation of several pro-apoptotic proteins, including Bax and PUMA, which promote mitochondrial outer membrane permeabilization (MOMP). This event results in cytochrome c release into the cytoplasm, initiating caspase activation and triggering the intrinsic apoptotic pathway. Additionally, CDK4 inhibition has been shown to enhance p53-dependent transcription of other apoptotic mediators, amplifying the cell death response in tumor cells with intact p53 function (26).

4.2 Bcl-2 Family Proteins Regulation

CDK4 inhibitors downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) by disrupting their transcriptional regulation and protein stability, thereby reducing their ability to inhibit mitochondrial outer membrane permeabilization. Simultaneously, they upregulate pro-apoptotic members (Bak, Bad) by enhancing their expression through transcriptional activation and post-translational modifications. This shift disrupts the delicate balance of survival and death signals, leading to increased mitochondrial cytochrome c release and activation of downstream apoptotic effectors, ultimately committing the cancer cells to programmed cell death (27).

4.3 Caspase Activation

Inhibition of CDK4 leads to the activation of initiator caspase-9 through the intrinsic (mitochondrial) apoptotic pathway, primarily mediated by cytochrome c release and apoptosome formation. This activation triggers the subsequent cleavage and activation of executioner caspase-3, which in turn degrades various structural and regulatory proteins, leading to DNA fragmentation, membrane blebbing, and eventual apoptotic cell death. Additionally, CDK4 inhibition enhances caspase-dependent cleavage of anti-apoptotic proteins, reinforcing the apoptotic cascade and ensuring effective elimination of cancer cells (28).

4.4 Evidence from Preclinical and Clinical Studies

Studies in breast cancer, melanoma, and glioblastoma models have demonstrated that CDK4 inhibition enhances apoptotic cell death by modulating key signaling pathways, including the p53-dependent intrinsic pathway and Bcl-2 family protein regulation. CDK4 inhibitors not only induce G1-phase arrest but also promote mitochondrial outer membrane permeabilization (MOMP), leading to cytochrome c release and caspase activation. Additionally, the apoptotic effects of CDK4 inhibition are significantly amplified when used in combination with other therapeutic agents, such as DNA-damaging chemotherapy, targeted inhibitors, and immune checkpoint blockade therapies. These synergistic effects improve treatment efficacy and reduce tumor resistance, highlighting the potential of CDK4 inhibitors as components of multimodal cancer therapy (29).

5. THERAPEUTIC POTENTIAL OF CDK4 INHIBITORS

CDK4 inhibitors have transformed cancer therapy, particularly in hormone receptor-positive breast cancer, where they have significantly improved progression-free survival and overall outcomes. Beyond breast cancer, their potential is being actively explored across various malignancies, including lung cancer, glioblastoma, and pancreatic cancer. These inhibitors not only exhibit efficacy as monotherapy but also demonstrate enhanced therapeutic impact when combined with chemotherapy, targeted therapies, and immunotherapy. Their ability to induce cell cycle arrest and modulate apoptotic pathways makes them a compelling addition to the oncological treatment landscape (30).

5.1 Monotherapy vs. Combination Therapy

CDK4 inhibitors have demonstrated significant anti-cancer activity as monotherapy by effectively halting cell cycle progression and preventing tumor proliferation. However, their efficacy can be limited by the emergence of resistance mechanisms that enable cancer cells to bypass CDK4 inhibition through alternative pathways such as cyclin E-CDK2 upregulation or activation of survival signaling cascades like PI3K/AKT (31). To overcome these challenges and enhance therapeutic outcomes, CDK4 inhibitors are increasingly being integrated into combination regimens alongside chemotherapy, immunotherapy, or endocrine therapy. When combined with chemotherapy, CDK4 inhibitors can induce cell cycle arrest, rendering tumor cells more vulnerable to DNA-damaging agents and promoting synergistic cytotoxic effects that amplify the impact of traditional chemotherapy drugs. In immunotherapy, CDK4 inhibitors have been shown to modulate the tumor microenvironment, increasing immune cell infiltration and enhancing the efficacy of immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 therapies, ultimately improving the body's ability to mount an effective anti-tumor immune response (32). In hormone-driven cancers, particularly estrogen receptor-positive (ER+) breast cancer, combining CDK4 inhibitors with endocrine therapy has become a cornerstone treatment strategy, significantly prolonging progression-free survival by delaying resistance to hormonal therapies. These combination approaches aim to not only extend the duration of response but also improve long-term survival rates by attacking cancer through multiple pathways simultaneously. As research advances, the future of CDK4 inhibitors will likely depend on the continued optimization of combination strategies, personalized to the molecular characteristics of each tumor to achieve the best possible therapeutic outcomes (33).

5.2 Clinical Trials and FDA Approvals

Clinical trials have played a pivotal role in establishing the therapeutic value of CDK4 inhibitors, particularly in advanced breast cancer. Multiple studies have demonstrated that these inhibitors significantly improve progression-free survival (PFS) and overall patient outcomes, leading to their widespread adoption in clinical practice. The success of landmark trials has resulted in the FDA approval of Palbociclib, Ribociclib, and Abemaciclib for hormone receptor-positive (HR+), HER2-negative breast cancer, where they are now standard treatment options in combination with endocrine therapy. Beyond breast cancer, ongoing clinical investigations are assessing the potential of CDK4 inhibitors in other malignancies, such as lung cancer, pancreatic cancer, and glioblastoma, where dysregulation of the CDK4/6 pathway is implicated in tumor progression (34). Preliminary findings indicate that these inhibitors may work synergistically with chemotherapy and immunotherapy by inducing cell cycle arrest, thereby enhancing the cytotoxic effects of chemotherapy and increasing tumor sensitivity to immune checkpoint inhibitors. Additionally, CDK4 inhibitors have been shown to promote apoptotic pathways in cancer cells, further contributing to tumor regression. As research continues, these findings suggest that CDK4 inhibitors could become an integral component of combination therapies across a broader range of cancers, potentially improving treatment efficacy and patient survival beyond their current indications (35).

6. CHALLENGES AND LIMITATIONS

CDK4 inhibitors, despite their promise, face several challenges that limit their effectiveness in cancer treatment. These challenges include the development of resistance, where cancer cells find alternative pathways to bypass CDK4 inhibition, reducing the drug's efficacy over time. Additionally, some tumors may exhibit intrinsic resistance due to genetic mutations in key regulators like the retinoblastoma (RB) protein, making CDK4 targeting less effective. Another significant issue is toxicity, with side effects such as neutropenia, gastrointestinal disturbances, and fatigue, which can impact patient compliance and treatment continuation. Furthermore, patient-specific variability in drug response makes it difficult to predict treatment outcomes, emphasizing the need for personalized therapeutic approaches. Researchers are addressing these challenges by exploring combination therapies with other targeted agents, developing next-generation inhibitors with improved specificity, and identifying biomarkers to better predict patient response to CDK4 inhibition (36). Despite their promise, CDK4 inhibitors face several challenges:

6.1 Resistance Mechanisms

Resistance to CDK4 inhibitors is a significant challenge in cancer therapy, limiting their long-term efficacy. Several mechanisms contribute to resistance, including genetic mutations, activation of compensatory pathways, and epigenetic modifications (37). One key mechanism involves the loss or mutation of the retinoblastoma (RB) protein, which renders CDK4 inhibition ineffective as RB is the primary downstream effector of CDK4 activity. Additionally, cancer cells may upregulate cyclin E-CDK2 activity, allowing them to bypass CDK4 inhibition and continue cell cycle progression. Activation of alternative signaling pathways, such as PI3K/AKT and MAPK, also promotes survival and proliferation despite CDK4 inhibition. Furthermore, epigenetic changes, including DNA methylation and histone modifications, can alter gene expression patterns, leading to adaptive resistance. Understanding these resistance mechanisms is crucial for

developing combination therapies and next-generation inhibitors to enhance treatment efficacy and overcome resistance (38).

6.2 Toxicity and Side Effects

The selected text discusses the common side effects of CDK4 inhibitors, which include neutropenia (a decrease in neutrophils, a type of white blood cell), fatigue, and gastrointestinal disturbances. These side effects may require adjustments in the dosage to ensure patient safety and tolerability. Neutropenia can increase the risk of infections, while fatigue can impact daily activities and quality of life. Gastrointestinal disturbances, such as nausea, diarrhea, or vomiting, can also affect patient compliance with the treatment. Dose modifications, supportive care, and close monitoring help manage these adverse effects, ensuring the effectiveness of CDK4 inhibitors while minimizing risks (39).

6.3 Strategies to Overcome Resistance

The section "Strategies to Overcome Resistance" briefly outlines three approaches to counteract resistance to CDK4 inhibitors in cancer therapy. First, it highlights the use of combination therapies targeting parallel pathways, which involves co-administering CDK4 inhibitors with other agents that block alternative survival mechanisms cancer cells may exploit (40). Second, it suggests a biomarker-based selection approach, where specific genetic or molecular markers are used to identify patients most likely to benefit from CDK4 inhibition, ensuring a more personalized and effective treatment. Finally, it mentions the development of next-generation inhibitors with improved selectivity, aiming to create more potent and precise drugs that minimize off-target effects and reduce the likelihood of resistance development. These strategies are crucial in addressing the limitations of current CDK4 inhibitors and improving long-term patient outcomes (41).

7. FUTURE PERSPECTIVES OF CDK4-TARGETED THERAPIES

The development of CDK4 inhibitors has been a major advancement in the treatment of cancer, particularly in hormone receptor-positive breast cancer and other malignancies characterized by dysregulated cell cycle progression. However, despite the initial success of CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib, challenges remain, including resistance mechanisms, dose-limiting toxicities, and patient heterogeneity in treatment response. As research progresses, the next generation of CDK4-targeted therapies aims to address these limitations through innovative approaches that enhance specificity, reduce side effects, and enable more personalized and durable treatment strategies (42).

7.1 Novel CDK4 Inhibitors

The first generation of CDK4/6 inhibitors has significantly improved clinical outcomes, particularly in patients with hormone receptor-positive (HR+), HER2-negative breast cancer. Their combination with endocrine therapy has become a cornerstone of treatment, demonstrating prolonged progression-free survival and improved disease control. However, the broad inhibition of both CDK4 and CDK6 has been associated with notable hematologic toxicities, such as neutropenia and anemia, largely due to CDK6's role in hematopoiesis. Furthermore, the emergence of resistance mechanisms over time limits the long-term efficacy of these drugs, necessitating the development of next-generation CDK4 inhibitors with improved pharmacological profiles (43). One of the primary advancements in second-generation CDK4 inhibitors is their enhanced selectivity for CDK4 over CDK6, which aims to retain strong anti-proliferative activity while minimizing bone marrow suppression and other hematologic toxicities. Since CDK6 is crucial for blood cell production, selectively inhibiting CDK4 is expected to reduce the incidence of severe neutropenia, making these therapies safer and more tolerable for long-term use. Additionally, novel CDK4 inhibitors are being optimized for improved pharmacokinetics and bioavailability, leading to better drug absorption, distribution, metabolism, and excretion (ADME) properties. These enhancements can result in more predictable drug exposure, sustained therapeutic activity, and potentially lower dosing frequencies, improving treatment outcomes (44).

A key challenge in CDK4/6-targeted therapy is the development of resistance, often driven by RB1 loss (retinoblastoma protein inactivation), cyclin E overexpression, or activation of compensatory cell cycle pathways. To overcome these resistance mechanisms, novel CDK4 inhibitors are being designed to target additional vulnerabilities within cancer cells, such as parallel cell cycle regulators and survival pathways, thereby enhancing their durability and effectiveness. Furthermore, efforts are being made to develop oral formulations that provide better patient compliance, especially in long-term treatment regimens where ease of administration is critical for adherence (45). Currently, these next-generation CDK4 inhibitors are undergoing preclinical and early-phase clinical trials, showing promising results in terms of efficacy, reduced toxicity, and potential for use beyond breast cancer. If successful, these novel inhibitors could expand therapeutic options, offering more durable responses and improved safety profiles, ultimately transforming the landscape of CDK4-targeted cancer therapy (46).

7.2 Role in Precision Medicine Approaches

The integration of precision medicine into oncology has revolutionized the approach to cancer diagnosis and treatment by leveraging genomic and transcriptomic profiling to tailor therapies to the molecular characteristics of an individual's tumor. CDK4 inhibitors are well-positioned to benefit from these advancements, as the identification of predictive biomarkers can significantly enhance patient selection, treatment optimization, and clinical outcomes (47).

One of the most critical aspects of precision medicine is biomarker-guided patient selection, which helps determine which patients are most likely to respond to CDK4 inhibitors. Research has shown that tumors with intact retinoblastoma (RB) protein function are more susceptible to CDK4 inhibition, as these drugs rely on RB phosphorylation blockade to induce cell cycle arrest. In contrast, tumors harboring RB1 mutations or deletions are often resistant to CDK4 inhibitors, as the drug's mechanism is ineffective in the absence of functional RB protein. Identifying these genetic alterations through next-generation sequencing (NGS) or liquid biopsy allows clinicians to make informed decisions about whether CDK4 inhibition is a viable treatment option, ensuring that patients receive therapies tailored to their tumor biology (48).

Beyond patient selection, precision medicine enables the development of combination strategies that target multiple oncogenic pathways simultaneously. By analyzing tumor-specific alterations, researchers can design rational combination therapies to enhance therapeutic efficacy and overcome resistance mechanisms. For instance, preclinical studies suggest that combining CDK4 inhibitors with PI3K, AKT, or mTOR inhibitors may be particularly effective in tumors with dysregulated PI3K signaling, a pathway that often contributes to cancer progression and drug resistance. Similarly, tumors with RAS pathway mutations may benefit from CDK4 inhibitors in combination with MEK or RAF inhibitors, as these drugs can work synergistically to block cancer cell proliferation and survival signals (49). These approaches enable personalized treatment regimens tailored to the molecular landscape of each tumor, maximizing the effectiveness of CDK4-targeted therapy.

Another key innovation in precision medicine is the use of liquid biopsy to enable real-time monitoring of tumor evolution through circulating tumor DNA (ctDNA) analysis. This approach allows clinicians to detect emerging resistance mutations and dynamically adjust treatment strategies as needed. For example, if a patient receiving CDK4 inhibitor therapy develops a resistance-associated mutation, oncologists can promptly modify the treatment plan by introducing alternative targeted agents or combination regimens to counteract resistance mechanisms. This adaptive treatment approach significantly improves long-term patient outcomes by ensuring that therapies remain effective as the tumor evolves (50).

By incorporating precision medicine principles, CDK4 inhibitors can be strategically deployed in clinical settings to maximize therapeutic benefit, ensuring that the right patients receive the right treatment at the right time. This personalized approach not only enhances efficacy but also reduces unnecessary exposure to ineffective treatments, ultimately improving overall survival and quality of life for cancer patients. As research in biomarker-driven oncology continues to evolve, the role of CDK4 inhibitors in precision medicine is expected to expand, unlocking new possibilities for targeted cancer therapy (51).

7.3 Role in Personalized Cancer Treatment

CDK4 inhibitors are increasingly being integrated into personalized cancer treatment strategies, where therapies are tailored to the molecular and genetic characteristics of an individual's tumor. Initially approved for hormone receptor-positive (HR+), HER2-negative breast cancer, these inhibitors are now being explored in a wider range of malignancies, including lung cancer, glioblastoma, melanoma, and sarcomas. By leveraging insights from tumor biology and precision medicine, researchers aim to enhance treatment efficacy, overcome resistance, and extend survival outcomes through targeted and combination approaches (52).

One of the most promising areas of CDK4 inhibitor application is in combination with immunotherapy. Emerging evidence suggests that CDK4 inhibitors can modulate the tumor microenvironment, leading to increased immune cell infiltration and enhanced response to immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 therapies. Since many cancers evade immune detection by creating an immunosuppressive microenvironment, CDK4 inhibition may help prime the immune system, making tumors more responsive to immunotherapeutic agents. This combination approach is particularly valuable in tumors with immune evasion mechanisms, where monotherapy with checkpoint inhibitors has shown limited effectiveness (53).

Beyond immunotherapy, CDK4 inhibitors are being studied in combination with other targeted therapies to exploit synergistic anti-cancer effects. For example, the successful combination of CDK4 inhibitors with endocrine therapy in estrogen receptor-positive (ER+) breast cancer has paved the way for their integration with other targeted agents. Expanding this strategy to include inhibitors of EGFR, HER2, and angiogenesis-related pathways could enhance tumor suppression and delay disease progression in cancers driven by these signaling mechanisms. Additionally, preclinical studies suggest that combining CDK4 inhibitors with PI3K,

AKT, or mTOR inhibitors may provide an effective strategy in tumors with aberrant PI3K pathway activation, a common feature of many solid tumors (54).

A significant challenge in CDK4-targeted therapy is drug resistance, which can limit long-term treatment effectiveness. Resistance mechanisms include the upregulation of cyclin E, activation of alternative survival pathways, or loss of retinoblastoma (RB) protein function, which is essential for CDK4 inhibitor activity. Preclinical and clinical studies are focused on identifying these resistance pathways and developing rational combination strategies to counteract them proactively. By integrating biomarker-driven patient selection with combination therapies that block compensatory survival mechanisms, researchers aim to extend the duration of response and improve patient survival outcomes (55).

Another crucial area of research is the broadening of CDK4 inhibitor applications beyond breast cancer. While these inhibitors have demonstrated strong clinical benefits in HR+ breast cancer, ongoing research is investigating their potential in other solid tumors and hematologic malignancies. Lung cancer, glioblastoma, and certain leukemias have shown promising preclinical responses to CDK4 inhibition, indicating that these drugs may have wider applicability in oncology. Clinical trials are now underway to determine the optimal settings for CDK4 inhibitor use in these malignancies, either as monotherapy or in combination with other therapeutic agents (56).

The integration of CDK4 inhibitors into personalized cancer treatment is a significant step toward precision oncology, where treatment decisions are guided by tumor-specific molecular profiles. By leveraging biomarker-driven strategies, combination therapies, and real-time treatment monitoring, CDK4 inhibitors have the potential to transform the therapeutic landscape and provide more effective, tailored treatment options for patients with diverse cancer types (57).

8. CONCLUSION

CDK4 inhibitors have revolutionized cancer therapy by targeting key regulatory mechanisms of the cell cycle and inducing apoptosis in tumor cells. By preventing the phosphorylation of the retinoblastoma (RB) protein, these inhibitors effectively halt cell cycle progression at the G1 phase, thereby restricting uncontrolled proliferation—a hallmark of cancer. Emerging evidence also suggests that CDK4 inhibitors contribute to apoptosis through multiple molecular pathways, including p53 activation, Bcl-2 family protein modulation, and caspase-dependent cell death. These dual effects enhance their therapeutic potential, making them valuable assets in oncology.

Currently, CDK4 inhibitors such as palbociclib, ribociclib, and abemaciclib have demonstrated significant clinical efficacy, particularly in hormone receptor-positive breast cancer, where they have improved progression-free survival and overall patient outcomes. Their application in other malignancies, including glioblastoma, melanoma, and lung cancer, is under active investigation, with promising preclinical and clinical results. However, despite their success, these inhibitors face significant challenges, including acquired resistance, tumor heterogeneity, and dose-limiting toxicities such as neutropenia and gastrointestinal side effects. Resistance mechanisms—such as RB1 loss, compensatory CDK2 activation, and alternative survival pathways involving PI3K/AKT and MAPK signaling—pose major hurdles in optimizing CDK4-targeted therapy. To address these limitations, ongoing research is focused on refining CDK4 inhibition strategies through combination therapies, biomarker-driven patient selection, and next-generation inhibitors with improved specificity and reduced toxicity.

Combining CDK4 inhibitors with immunotherapy, targeted agents, or chemotherapy has shown promise in overcoming resistance and enhancing therapeutic efficacy. Furthermore, advances in precision medicine, including genomic profiling and liquid biopsy-based monitoring, are paving the way for more personalized treatment approaches, ensuring that CDK4 inhibitors are used in patients most likely to benefit. Looking ahead, the future of CDK4-targeted therapies is promising. The development of more selective inhibitors with reduced toxicity and the integration of CDK4 inhibition into precision oncology will likely expand their clinical applications. As research continues to uncover the intricate molecular mechanisms governing CDK4-mediated tumor progression and apoptosis, new therapeutic opportunities will emerge. Ultimately, CDK4 inhibition stands as a cornerstone of modern oncology, with the potential to improve patient outcomes across a broad spectrum of malignancies. Continued advancements in drug development, resistance management, and personalized medicine will further solidify their role in the evolving landscape of cancer treatment.

ACKNOWLEDGMENTS:

For providing the facilities, the authors would like to thank the principal of Shri Vile Kelavani Mandal's Institute of Pharmacy in Dhule, Maharashtra. We especially thank Mr. Sagar More and Mr. Devendra Jadhav (Inkwell Research Solution) for their assistance in making tables and providing valuable insights on this review article.

AUTHORS' CONTRIBUTIONS

Writing, Data curation, Review, and editing: S.V.P.; Conceptualization, Supervision, Review, and editing: S.V.P. and Y.V.P. All authors read and approved the final manuscript.

REFERENCES:

1. Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020 Mar 13;21(6):1960.
2. Pandey K, An H, Kim SK, Lee SA, Kim S, Lim SM, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer. 2019 Sep 1;145(5):1179–88.
3. Goel S, Bergholz JS, Zhao JJ. Targeting cyclin-dependent kinases 4 and 6 in cancer. Nat Rev Cancer. 2022 Jun;22(6):356–72.
4. Baker SJ, Poulikakos PI, Irie HY, Parekh S, Reddy EP. CDK4: a master regulator of the cell cycle and its role in cancer. Genes Cancer. 2022 Aug 25;13:21–45.
5. Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science. 2022 Jan 14;375(6577):eabc1495.
6. Topacio BR, Zatulovskiy E, Cristea S, Xie S, Tambo CS, Rubin SM, et al. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix. Mol Cell. 2019 May 16;74(4):758-770.e4.
7. Pandey K, An H, Kim SK, Lee SA, Kim S, Lim SM, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer. 2019 Sep 1;145(5):1179–88.
8. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene Amplification and Overexpression of CDK4 in Sporadic Breast Carcinomas Is Associated with High Tumor Cell Proliferation. Am J Pathol. 1999 Jan;154(1):113–8.
9. Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848.
10. Johnston S, Emde A, Barrios C, Srock S, Neven P, Martin M, et al. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences. JNCI Cancer Spectr. 2023 Jun 27;7(4):pkad045.
11. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res BCR. 2009;11(5):R77.
12. Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, et al. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. The Oncologist. 2022 Aug 2;27(10):811–21.
13. Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2021;81(3):317–31.
14. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018 Nov;28(11):911–25.
15. Scheidemann ER, Shajahan-Haq AN. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Int J Mol Sci [Internet]. 2021 Nov 14 [cited 2025 Mar 9];22(22):12292. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625090/
16. Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs [Internet]. 2021 [cited 2025 Mar 9];81(3):317–31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952354/
17. Corona SP, Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321–30.
18. Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol Off J Eur Soc Med Oncol. 2019 Oct 1;30(10):1613–21.
19. Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, et al. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Res BCR [Internet]. 2020 [cited 2025 Mar 9];22:87. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425060/
20. Dey J, Deckwerth TL, Kerwin WS, Casalini JR, Merrell AJ, Grenley MO, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2

inhibition. Sci Rep [Internet]. 2017 Dec 21 [cited 2025 Mar 9];7:18007. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740070/

21. Lin J, Yan XJ, Chen HM. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. Cancer Chemother Pharmacol. 2007 Mar;59(4):439–45.

22. Ruglioni M, Crucitta S, Luculli GI, Tancredi G, Del Giudice ML, Mechelli S, et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit Rev Oncol Hematol [Internet]. 2024 Sep 1 [cited 2025 Mar 9];201:104424. Available from: https://www.sciencedirect.com/science/article/pii/S1040842824001677

23. Goel S, Bergholz JS, Zhao JJ. Targeting cyclin-dependent kinases 4 and 6 in cancer. Nat Rev Cancer [Internet]. 2022 Jun [cited 2025 Mar 9];22(6):356–72. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149100/

24. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018 Nov;28(11):911–25.

25. Sharma A, Boise LH, Shanmugam M. Cancer Metabolism and the Evasion of Apoptotic Cell Death. Cancers. 2019 Aug 9;11(8):1144.

26. DeVine T, Dai MS. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des. 2013;19(18):3248–62.

27. Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022 Oct 12;12:985363.

28. Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, et al. Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications. Cells. 2024 Nov 6;13(22):1838.

29. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018 Nov;28(11):911–25.

30. Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018 Jul 17;10:1758835918786451.

31. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018 Nov;28(11):911–25.

32. Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall'Acqua A, Vecchione A, Baldassarre G, et al. CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Front Oncol. 2022 May 27;12:891580.

33. Zhou FH, Downton T, Freelander A, Hurwitz J, Caldon CE, Lim E. CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Front Cell Dev Biol. 2023 Mar 22;11:1148792.

34. Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848.

35. Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall'Acqua A, Vecchione A, Baldassarre G, et al. CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Front Oncol. 2022 May 27;12:891580.

36. Lee JS, Hackbart H, Cui X, Yuan Y. CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions. Int J Mol Sci. 2023 Jul 22;24(14):11791.

37. Pandey K, An H, Kim SK, Lee SA, Kim S, Lim SM, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer. 2019 Sep 1;145(5):1179–88.

38. Pandey K, An H, Kim SK, Lee SA, Kim S, Lim SM, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer. 2019 Sep 1;145(5):1179–88.

39. Stanciu IM, Parosanu AI, Nitipir C. An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials. Biomolecules. 2023 Sep 20;13(9):1422.

40. Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers. 2022 Sep 19;14(18):4543.

41. Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers. 2022 Sep 19;14(18):4543.

42. Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848.

43. Kimmick G, Pilehvari A, You W, Bonilla G, Anderson R. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting. Breast Cancer Res Treat. 2024;208(2):263–73.

44. Yuan K, Wang X, Dong H, Min W, Hao H, Yang P. Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharm Sin B. 2021 Jan;11(1):30–54.

45. Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer. 2017 Jan;3(1):39–55.

46. Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848.

47. Masucci M, Karlsson C, Blomqvist L, Ernberg I. Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine. J Pers Med. 2024 May 24;14(6):561.

48. Schoninger SF, Blain SW. The ongoing search for biomarkers of CDK4/6 inhibitor responsiveness in Breast Cancer. Mol Cancer Ther. 2020 Jan;19(1):3–12.

49. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, et al. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov. 2022 Jun 2;12(6):1542–59.

50. Adhit KK, Wanjari A, Menon S, K S. Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis and Monitoring in Medicine. Cureus. 15(12):e50176.

51. Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848.

52. Zhao M, Hanson KA, Zhang Y, Zhou A, Cha-Silva AS. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review. Target Oncol. 2023;18(3):327–58.

53. Lelliott EJ, Sheppard KE, McArthur GA. Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything? NPJ Precis Oncol. 2022 Apr 20;6:26.

54. Xue Y, Zhai J. Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance. Int J Clin Exp Pathol. 2024 Jul 15;17(7):189–207.

55. Asghar US, Kanani R, Roylance R, Mittnacht S. Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. JCO Precis Oncol. 2022 Jan 6;6:e2100002.

56. Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848.

57. Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall'Acqua A, Vecchione A, Baldassarre G, et al. CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Front Oncol. 2022 May 27;12:891580.